Cargando…

Case Report: Primary and Acquired Resistance Mechanisms of Nimotuzumab in Advanced Esophageal Squamous Cell Carcinoma Revealed by Targeted Sequencing

Esophageal squamous cell carcinoma (ESCC) is a deadly disease with a low 5-year survival rate. Anti-epidermal growth factor receptor (EGFR) therapy has been widely used in the treatment of malignancies, and chemotherapy regimens that include nimotuzumab have been confirmed to have satisfactory effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Dantong, Yan, Weihua, Zhu, Hua, Liu, Qiaoling, Hou, Helei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658551/ https://www.ncbi.nlm.nih.gov/pubmed/33194681 http://dx.doi.org/10.3389/fonc.2020.574523

Ejemplares similares

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Combined Nimotuzumab with Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Thai Hoa, Nguyen Thi, et al.
Publicado: (2020)

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study
por: Hu, Jing, et al.
Publicado: (2022)

Nimotuzumab plus induction chemotherapy followed by radiotherapy/concurrent chemoradiotherapy plus nimotuzumab for locally advanced nasopharyngeal carcinoma: protocol of a multicentre, open-label, single-arm, prospective phase II trial
por: Yuan, Jing-Jing, et al.
Publicado: (2022)

Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
por: Wang, Lili, et al.
Publicado: (2023)

Study on chemotherapeutic sensitizing effect of nimotuzumab on different human esophageal squamous carcinoma cells
por: YANG, XIAOYU, et al.
Publicado: (2016)

Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma
por: Xu, Zhonghua, et al.
Publicado: (2020)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3
por: Zhao, Lei, et al.
Publicado: (2012)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Comparative Genomic Analysis Reveals Genetic Variations in Multiple Primary Esophageal Squamous Cell Carcinoma of Chinese Population
por: Liang, Jinxiao, et al.
Publicado: (2022)

RNA Sequencing of Tumor-Educated Platelets Reveals a Three-Gene Diagnostic Signature in Esophageal Squamous Cell Carcinoma
por: Liu, Tiejun, et al.
Publicado: (2022)

Genomic Variations in Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
por: Yasar, Hatime A
Publicado: (2023)

Chemoradiotherapy Versus Chemotherapy Alone for Advanced Esophageal Squamous Cell Carcinoma: The Role of Definitive Radiotherapy for Primary Tumor in the Metastatic Setting
por: Li, Li-Qing, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
por: González Fernández, Sandra, et al.
Publicado: (2022)

Serum Metabolomic Profiling Reveals Biomarkers for Early Detection and Prognosis of Esophageal Squamous Cell Carcinoma
por: Wang, Pan Pan, et al.
Publicado: (2022)

Plasma Metabolomics Reveals Diagnostic Biomarkers and Risk Factors for Esophageal Squamous Cell Carcinoma
por: Yu, Mengjie, et al.
Publicado: (2022)

Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer
por: Han, Xinghua, et al.
Publicado: (2017)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting
por: Zhou, Yi-Xin, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Induction chemotherapy increases efficacy and survival rate of patients with locally advanced esophageal squamous cell carcinoma
por: Huang, Yuting, et al.
Publicado: (2022)

Nimotuzumab combined with concurrent chemoradiotherapy benefits patients with advanced nasopharyngeal carcinoma
por: Li, Zhanzhan, et al.
Publicado: (2017)

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials
por: Yuan, Yan, et al.
Publicado: (2022)

Postoperative serum squamous cell carcinoma antigen and carcinoembryonic antigen predict overall survival in surgical patients with esophageal squamous cell carcinoma
por: Huang, Yi, et al.
Publicado: (2023)

Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
por: Liu, Shixian, et al.
Publicado: (2022)

Mutational Landscape of Esophageal Squamous Cell Carcinoma in an Indian Cohort
por: Mangalaparthi, Kiran K., et al.
Publicado: (2020)

Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Subtype-Based Analysis of Cell-in-Cell Structures in Esophageal Squamous Cell Carcinoma
por: Wang, Yuqi, et al.
Publicado: (2021)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Comprehensive Analysis of Competitive Endogenous RNAs Network, Being Associated With Esophageal Squamous Cell Carcinoma and Its Emerging Role in Head and Neck Squamous Cell Carcinoma
por: Yu, Donghu, et al.
Publicado: (2020)

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair
por: Liu, Hai, et al.
Publicado: (2015)

Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma
por: Chen, Hai-yan, et al.
Publicado: (2014)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Advancement in research and therapy of NF1 mutant malignant tumors
por: Tao, Junyan, et al.
Publicado: (2020)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lhb1ro5cdvb5rkd1d0donml86f